DexCom (NASDAQ:DXCM) PT Raised to $145.00 : vimarsana.com

DexCom (NASDAQ:DXCM – Get Free Report) had its price objective raised by equities researchers at Canaccord Genuity Group from $144.00 to $145.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s price target points to a potential upside of […]

Related Keywords

United States , Massachusetts , Canada , Raymond James , Michael Jon Brown , Matthew Vincent Dolan , Norges Bank , Securities Exchange Commission , Capital Research Global Investors , Royal Bank , Artisan Partners Limited Partnership , Canaccord Genuity Group , Dexcom Company Profile , Massachusetts Financial Services Co , Citigroup , Dexcom Inc , Get Free Report , Genuity Group , Jon Brown , Exchange Commission , Vincent Dolan , World Investors , Partners Limited Partnership , Research Global Investors , Massachusetts Financial Services , Dexcom Share , Dexcom Real Time , Dexcom Daily , Dexcom , Nasdaq Dxcm , Dxcm , Medical , 25213110 , Boost Price Target , Canaccord Genuity Group Inc ,